Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MARIMED INC.MRMD · Entity 7423 | Chief Commercial Officer | October 15, 2026 | October 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MARIMED INC.
Report date October 15, 2026 · Filed October 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 1,151,378 |
Ending reported balance
After 2026-10-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-15 · Exercise / conversion · Acquired 32,812 · Balance 1,161,009 F1: RSUs convert to shares of common stock on a one-for-one basis. Row 2 · 2026-10-15 · Tax withholding · Disposed 9,631 · Balance 1,151,378 F2: Reflects shares of common stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs. |
| Restricted Stock Units (RSU)SEC Table II · derivative / convertible security | Direct | 65,625 |
Reported balance
After 2026-10-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-15 · Exercise / conversion · Disposed 32,812 · Balance 65,625 F1: RSUs convert to shares of common stock on a one-for-one basis. F3: The RSUs were granted on April 15, 2026; the remaining RSUs under this grant will vest as follows: 32,813 on January 15, 2027 and 32,812 on April 15, 2027, in accordance with the terms of an award agreement between the Issuer and the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: RSUs convert to shares of common stock on a one-for-one basis.
F2: Reflects shares of common stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs.
F3: The RSUs were granted on April 15, 2026; the remaining RSUs under this grant will vest as follows: 32,813 on January 15, 2027 and 32,812 on April 15, 2027, in accordance with the terms of an award agreement between the Issuer and the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 09, 2025 Filed May 12, 2025 20:33 UTC | MARIMED INC. MRMD · Entity 7423 | GrantRestricted Stock Units (RSU) · Derivative | 188,705 | $0.00 | $0.00 |
DisclosureSEC source: 0001522767-25-000064 · wk-form4_1747082023.xml · derivative · entry 2 Crandall Ryan · CIK 0002062820 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 188,705 Underlying: Common Stock, par value $.001 per share · 188,705 shares Expires not disclosed F1 · derivative.exercise_price: RSUs convert to shares of common stock on a one-for-one basis. F2 · derivative.exercise_date: The RSUs will vest in three equal installments on June 15, 2025, September 15, 2025 and December 15, 2025 in accordance with the terms of an agreement between the Issuer and the Reporting Person. F2 · derivative.expiration_date: The RSUs will vest in three equal installments on June 15, 2025, September 15, 2025 and December 15, 2025 in accordance with the terms of an agreement between the Issuer and the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.